US 12,351,578 B2
Compounds for inhibiting NLRP3 and uses thereof
Stéphane Dorich, Pointe-Claire (CA); and Miguel St-Onge, Saint-Lazare (CA)
Assigned to Ventus Therapeutics U.S., Inc., Waltham, MA (US)
Filed by Ventus Therapeutics U.S., Inc., Waltham, MA (US)
Filed on Oct. 26, 2022, as Appl. No. 17/974,342.
Application 17/974,342 is a continuation of application No. 17/679,898, filed on Feb. 24, 2022.
Application 17/679,898 is a continuation of application No. 17/528,928, filed on Nov. 17, 2021, granted, now 11,319,319, issued on May 3, 2022.
Claims priority of provisional application 63/171,932, filed on Apr. 7, 2021.
Prior Publication US 2023/0159526 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/5377 (2006.01); C07D 405/12 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/501 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/5377 (2013.01); C07D 405/12 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 519/00 (2013.01)] 20 Claims
 
1. A method of treating a disease, condition, or disorder comprising administering to a human subject in need thereof a compound of Formula (II-h):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is

OG Complex Work Unit Chemistry
Y is phenyl independently substituted with one, two, or three substituents selected from the group consisting of C1-C6 haloalkyl, halo, and —R4OR5;
R2a is hydrogen;
R4 is a bond; and
R5 is hydrogen;
wherein treating is alleviation of an established symptom of said disease, condition or disorder in said human subject, and
wherein said disease, condition or disorder is selected from the group consisting of a liver disease, a kidney disease, and a cardiovascular disease.